28 results about "CD20" patented technology

The present disclosure provides CD19 / CD20-binding domains and chimeric antigen receptors (CARs) based on the same, as well as corresponding nucleic acid molecules, vectors, cells, compositions, methods and uses, e.g., for the prevention and / or treatment of cancer and / or autoimmune disease.

Disclosed herein, in on aspect, is a method of treating an immune or inflammatory disease, comprising administering to a subject in need thereof a therapeutically effective amount of an antibody or antigen-binding fragment thereof that binds to CD20 and CD3, thereby treating the immune or inflammatory disease.

This application provides a new NMT inhibitor and an antibody-drug conjugate (ADC) that comprises the NMT inhibitor as the payload tethered to an antibody, as well as a method for treating or preventing a disease or disorder associated with NMT, such as cancer associated with a cancerous cell that expresses HER2, CD19, CD20, or CD276 / 87-H3).

Aspects of the disclosure include methods of treating an autoimmune disease, including reducing the need for chronic immunosuppression, and for effectuating immune reset and / or producing a naive B cell repertoire in a subject in need thereof, the methods comprising administering a therapeutically effective amount of anti-CD20 yδ T cells to the subject, wherein the anti-CD20 yδ T cells express a chimeric antigen receptor (CAR) comprising a binding domain that specifically binds to CD20.

The application discloses a kind of bispecific anti-CD3 / CD20 antibodies and its application in B cell lymphoma, belong to the field of biological medicine technology.The bispecific antibody uses "tandem type" molecular structure, by the single-chain antibody (scFv) of anti-CD20 and the nanometer antibody (VHH) of anti-CD3 are fused by flexible connecting peptide.The high-purity bispecific antibody BsAb-20S3V is obtained by CHO cell stable expression system, and it has nanomolar level affinity to CD20+ and CD3+ cells.Experiments in vitro prove that the antibody can effectively mediate T cell specific killing to Raji cell, and the maximum killing rate can reach 75%-90%.In vivo pharmacodynamic evaluation shows that in tumor-bearing mouse model, high-dose group can significantly inhibit tumor growth and induce tumor negative growth.The antibody has good potential to prepare B cell lymphoma treatment drugs.

Provided is a use of a recombinant fusion protein in the preparation of a drug for treating an autoimmune disease that can benefit from the reduction or elimination of CD20+B cells (for example, CD20+ B cell depletion therapy). The recombinant fusion protein comprises i) a CD47-binding peptide, and ii) an anti-CD20 antibody or an antigen-binding portion thereof, wherein the CD47-binding peptide comprises a first extracellular Ig-like domain (SIRPαD1) of signal regulatory protein α (SIRPα), and the anti-CD20 antibody or the antigen-binding portion thereof comprises a heavy chain variable region, a heavy chain constant region, a light chain variable region, and a light chain constant region. The heavy chain variable region comprises VH-CDR1, VH-CDR2, and VH-CDR3, and the light chain variable region comprises VL-CDR1, VL-CDR2, and VL-CDR3, wherein the VH-CDR1, VH-CDR2, VH-CDR3, VL-CDR1, VL-CDR2, and VL-CDR3 respectively comprise amino acid sequences as shown in GYTFTSYN (SEQ ID NO: 1), IYPGNGDT (SEQ ID NO: 2), ARSTYYGGDWYFNV (SEQ ID NO: 3), SSVSY (SEQ ID NO: 4), ATS, and QQWTSNPPT (SEQ ID NO: 5). The heavy chain constant region has the binding capacity for an FcR or a complement system protein. The CD47-binding peptide is linked to the N-terminus of the heavy chain variable region or light chain variable region of the anti-CD20 antibody or the antigen-binding portion thereof.

The present invention relates to administration regimens for therapeutic proteins (e.g., bispecific antibodies that activate T cells) that mitigate cytokine release syndrome and infusion-related reactions. The methods employ an initial fractionated dosing with the optional administration of additional agents such as steroids or cytokine antagonists, which are discontinued at the maximum weekly dosage during the course of the dosing regimen.

Provided herein are novel anti-CD20x anti-CD28 antibodies and methods of using such antibodies to treat B cell malignancies. The subject anti-CD20x anti-CD28 antibodies are capable of agonically binding to a CD28 costimulatory molecule on a T cell and to CD20 on a tumor cell. Thus, such antibodies enhance anti-tumor activity at tumor sites. The subject antibodies provided herein are particularly useful in the treatment of B-cell malignancies in combination with other anti-cancer therapies (e.g., anti-CD3 x anti-CD20 x anti-CD79b antibodies).

Various embodiments of the present application provide binding molecules for B-lymphocyte antigens (e.g., CD19 and CD20), including antigen recognizing receptors (e.g., CARs) that target B-lymphocyte antigens (e.g., CD19 and CD20). Embodiments of the present application also provide cells expressing such binding molecules, therapeutic compositions comprising such cells, and methods for treating diseases or disorders associated with B-lymphocyte antigens (e.g., CD19 and CD20), including hematological cancers, autoimmune diseases (e.g., multiple sclerosis and systemic lupus erythematosus).

The present application relates to a preparation method of a CD20 antibody conjugated drug, the antibody conjugated drug and the use thereof. Specifically, the present application discloses a CD20 antibody conjugated drug as shown in general formula I. The antibody conjugated drug has a significant anti-tumor effect.

This application provides a new NMT inhibitor and an antibody-drug conjugate (ADC) that comprises the NMT inhibitor as the payload tethered to an antibody, as well as a method for treating or preventing a disease or disorder associated with NMT, such as cancer associated with a cancerous cell that expresses HER2, CD 19, CD20, or CD276 / 87-H3).

Disclosed are combinations comprising a therapeutically effective amount of a menin-MLL inhibitor of Formula (I) or a pharmaceutically acceptable salt or a solvate thereof; and a therapeutically effective amount of at least one other therapeutic agent which is a hypomethylating agent, a cytidine deaminase inhibitor, a DNA intercalating agent, a pyrimidine analog, a purine analog, a kinase inhibitor, a CD20 inhibitor, an IDH inhibitor, an immunomodulatory agent or a DHODH inhibitor. Also disclosed are methods for treating a subject who has been diagnosed with cancer using such combinations. Compounds are represented by Formula (I) as follows:wherein the variables are defined herein.

The present disclosure relates to antibodies and antibody-drug conjugates (ADCs) targeting CD79b and / or CD20 and compositions containing the antibodies or ADCs and therapeutic applications thereof.

The present application belongs to the field of biotechnology, and particularly relates to a CD20 nanobody and a preparation method and application thereof. The nanobody can specifically recognize and combine with CD20, and has good affinity therewith, and can be used for preparing products for diagnosing, preventing or treating diseases or disorders related to B cells and / or CD20, or detecting the presence or level of CD20 in a sample.

The present invention relates to an engineered cell comprising at least one chimeric antigen receptor polypeptide specific for CD19 and CD20, a pharmaceutical composition comprising the engineered cell, a nucleic acid or vector comprising a nucleotide sequence encoding the chimeric antigen receptor polypeptide specific for CD19 and CD20 and a kit comprising the engineered cell, in particular for use in the treatment of cancer, infectious disease or autoimmune disease.

A CD19-OR-CD20 chimeric antigen receptor (CAR) protein construct is provided. Also provided are nucleic acids encoding the CD19-OR-CD20 CAR; and methods of use, e.g. in the treatment of B cell malignancies. The CD19-OR-CD20 CAR of the invention is a bispecific CAR than can trigger T-cell activation upon detection of either CD19 or CD20 (or both). IT is a single molecule that confers two-input recognition capability upon human T cells engineered to stably express this CAR.

The present disclosure provides methods of treating a systemic lupus erythematosus (e.g. highly active, severe, treatment-refractory systemic lupus erythematosus) by administering a chimeric antigen receptor T cell (CAR-T cell) comprising an anti-CD20 chimeric antigen receptor and an anti-CD19 chimeric antigen receptor. The present disclosure also provides a dose infusion bag comprising a composition comprising CAR-T cells comprising an anti-CD20 chimeric antigen receptor and an anti-CD19 chimeric antigen receptor.

Provided herein are methods for: (1) rapidly depleting circulating B cells and remodeling one or more B cell compartments, (2) treating B cell-related autoimmune diseases, and (3) B cell malignancies, using B cell depleting antibodies that are directed to CD19 or CD20 and one or more target antigens. Further provided herein is a CD19 / CD20 bispecific antibody with dual Fc domains that mediate enhanced effector functions and B cell depletion. HB2198 demonstrated enhanced binding to Fcγ receptors, potent effector functions, and efficient depletion of B cells in vitro and in vivo.

The present disclosure provides bispecific chimeric antigen receptors targeting CD20 and BCMA. The CAR may comprise an scFv targeting CD20 and an scFv targeting BCMA, a hinge region, a transmembrane domain, a co-stimulatory region, and a cytoplasmic signaling domain. The chimeric antigen receptors can be used to treat autoimmune disorders or cancer.

This application relates to a method, system, device, and medium for predicting colorectal cancer recurrence based on pathological features. The method includes: screening colorectal cancer subjects; obtaining paraffin-embedded tumor tissue blocks, clinicopathological data, and long-term follow-up data containing recurrence records; obtaining HE-stained sections and CD3 / CD20 / CD21 / CD23 immunohistochemical sections; identifying the tertiary lymphoid structures of the tumor and pre-defined boundary regions; extracting their density and maturity characteristics and traditional pathological features; integrating them into a standardized feature set; correlating the feature set with follow-up data; and screening for independent influencing factors of recurrence using univariate / multivariate logistic regression; constructing and validating a nomogram prediction model; and using it for recurrence risk assessment in newly postoperative patients. This method, by integrating tertiary lymphoid structure features with traditional pathological features and constructing a nomogram prediction model based on multivariate analysis, improves the accuracy and reliability of colorectal cancer recurrence risk prediction, providing more precise prognostic assessment and personalized treatment decision support for clinicians.

Provided are an antibody targeting CD79b and / or CD20, an antibody-drug conjugate (ADC), a composition containing the antibody or ADC, and the therapeutic use thereof.

The present disclosure provides compositions and methods for inhibiting or preventing an immune response to an immunogen (e.g., an immunogenic delivery vehicle) in a subject in need thereof, comprising administering to the subject an effective amount of a plasma cell depleting agent, e.g., an antigen-binding molecule that binds to B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) (e.g., an anti-BCMAxCD3 bispecific antibody, or a functional fragment thereof) or a B cell depleting agent, e.g., an antigen-binding molecule that binds to CD20 and CD3 (e.g., an anti-CD20xCD3 bispecific antibody, or a functional fragment thereof), either alone or in combination with one another, and / or in combination with an immunoglobulin depleting agent such as a neonatal fragment crystallizable (Fc) receptor (FcRn) blocker (e.g., efgartigimod).

The present invention is concerned with a human CD20 protein with modifications to one or more intracellular domains sufficient to reduce or abrogate intracellular signalling when attached to or associated with the membrane of the cell such as (e.g.) a T-cell, a natural killer cell, a B-cell, a myeloid cell, a pluripotent stem cell and a haematopoietic stem cell. The present invention further contemplates a nucleic acid encoding a modified human CD20 protein described herein, and to the utility of the modified human CD20 protein as a safety switch in chimeric antigen receptor T-cell therapy or as a selection marker for gene therapies.

Provided are an antigen binding molecule specifically binding to CD19, CD20 and CD3, and a pharmaceutical use thereof. Further provided is a use of a trispecific antibody specifically binding to CD19, CD20 and CD3 in the preparation of a drug for treating a tumor and an autoimmune disease.

Provided herein are therapeutic agents, pharmaceutical compositions, and methods comprising an IgA constant region. The compositions and methods described herein facilitate binding of an antibody construct comprising an IgA constant domain to CD47 and an antigen for instance a tumor related antigen such as CD20 or CD19.